OakChart

Pulmonx Corp

LUNGHealthcare·Medical Devices·USA·Micro·NASD·Nov 11 • 3:59 PM ET

2.98+0.18 (6.43%)
2026-11-12 04:03 CET
Market cap
129.78 USD m
Revenue, TTM
88.78 USD m
Net income, TTM
-42.55 USD m
Free cash flow, TTM
-26.12 USD m
EPS diluted, TTM
-1.01
P/E
-
Compare

Price

LUNG against its 20, 50 and 200-day averages
2050200beat
1.502.002.503.003.6M7.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26LUNGclose 2.9820-day 2.3650-day 2.11200-day 1.692.9852w high52w low

8.3% under the 52-week high of 3.25 on 29 Oct 2026. 52-week low 1.13 on 30 Mar 2026. Last 15 sessions, 81.6% high to low

Volume 1.48× normal · the line is the 50-bar volume average

Profile

LUNG
52-week range, 87% of the way up
1.133.25

Pulmonx Corp. is a medical technology company, which engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. It operates through the following geographical segments: United States, Europe, Middle East, Africa, Asia Pacific, and Other International. The company was founded by Rodney Perkins on December 26, 1995 and is headquartered in Redwood City, CA.

Employees296
IPOOct 01, 2020
Beta0.18
ATR, 14d0.27
Rel volume1.48
Short float2.02%
Insider own10.48%
Inst own60.50%

Snapshot

6 groups

Valuation

Index-
Market Cap129.78M
Enterprise Value133.18M
Income-42.55M
Sales88.78M
Book/sh0.79
Cash/sh1.22
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees296
IPOOct 01, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S1.46
P/B3.79
P/C2.45
P/FCF-
EV/EBITDA-
EV/Sales1.50
Quick Ratio3.30
Current Ratio4.04
Debt/Eq1.65
LT Debt/Eq1.60
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.01
EPS next Y-0.92
EPS next Q-0.22
EPS this Y27.22%
EPS next Y5.17%
EPS next 5Y18.00%
EPS past 3/5Y5.81% -8.01%
Sales past 3/5Y19.03% 22.55%
EPS Y/Y TTM28.45%
Sales Y/Y TTM-3.15%
EPS Q/Q42.97%
Sales Q/Q6.20%
EarningsOct 27 AMC
EPS/Sales Surpr.25.95% 4.11%

Ownership

Insider Own10.48%
Insider Trans-3.62%
Inst Own60.50%
Inst Trans-11.63%
ROA-34.25%
ROE-90.31%
ROIC-47.78%
Gross Margin77.08%
Oper. Margin-44.39%
Profit Margin-47.93%
SMA2026.30%
SMA5041.21%
SMA20076.08%
Trades-

Technical

Shs Outstand43.55M
Shs Float38.99M
Short Float2.02%
Short Ratio1.28
Short Interest0.79M
52W High3.25 -8.31%
52W Low1.13 163.72%
Volatility13.33% 10.80%
ATR (14)0.27
RSI (14)65.90
Beta0.18
Rel Volume1.48
Avg Volume613.55K
Volume905,553

Performance

Perf Week5.30%
Perf Month69.32%
Perf Quarter37.96%
Perf Half Y124.06%
Perf YTD34.84%
Perf Year42.58%
Perf 3Y-67.78%
Perf 5Y-92.85%
Perf 10Y-
Recom1.80
Target Price3.70
Prev Close2.80
Price2.98
Change %6.43%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jul 31, 2025DowngradePPiper SandlerOverweight → Neutral$2.50-16.1%
Mar 10, 2025InitiatedDD. Boral CapitalBuy$17+470.5%
Dec 11, 2024DowngradeCCitigroupBuy → Neutral$17 → $7.50+151.7%
Jun 04, 2024InitiatedLLake StreetBuy$12+302.7%
Feb 23, 2024DowngradeWWells FargoOverweight → Equal Weight$16 → $14+369.8%
Sep 05, 2023InitiatedCCraig HallumBuy$18+504.0%
Feb 27, 2023UpgradeWWells FargoEqual Weight → Overweight$10 → $15+403.4%
Jan 03, 2023DowngradeBBofA SecuritiesNeutral → Underperform$8+168.5%
Dec 12, 2022UpgradeCCitigroupNeutral → Buy$14 → $10+235.6%
Jul 11, 2022DowngradeCCitigroupBuy → Neutral$23 → $19+537.6%

Peers

Mkt cap
TickerCompanyMkt cap
INGNInogen Inc149.51M
INSPInspire Medical Systems Inc1.80B
ELMDElectromed Inc206.84M
VMDViemed Healthcare Inc345.96M
NYXHNyxoah SA91.66M
PRCTProcept BioRobotics Corp1.34B
CVCapsoVision Inc333.63M
XAIRBeyond Air Inc4.38M
LIVNLivaNova PLC5.01B
MDTMedtronic Plc129.98B

Insider trading

latest 14 of 21
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
French Glendon E. IIIPresident and CEOSep 01 '26Sale2.2641,88294,6531,137,936Sep 03 06:23 PM
Radhakrishnan SrikanthChief Science & Techn. OfficerSep 01 '26Sale2.2614,24532,194316,994Sep 03 06:21 PM
Lehman David AaronGeneral CounselSep 01 '26Sale2.2614,33432,395361,827Sep 03 06:19 PM
Rose Geoffrey BeranChief Commercial OfficerSep 01 '26Sale2.267,87917,807449,832Sep 03 06:17 PM
Radhakrishnan SrikanthChief Science &Techn. OfficerJun 01 '26Sale1.5414,49722,325331,239Jun 03 04:18 PM
Lehman David AaronGENERAL COUNSELJun 01 '26Sale1.5414,59422,475376,161Jun 03 04:17 PM
Rose Geoffrey BeranCHIEF COMMERCIAL OFFICERJun 01 '26Sale1.548,02312,355457,711Jun 03 04:16 PM
French Glendon E. IIIPresident and CEOJun 01 '26Sale1.5442,63865,6631,191,673Jun 03 04:15 PM
French Glendon E. IIIPresident and CEOJun 02 '26Sale1.5713,51121,2121,178,162Jun 03 04:15 PM
Radhakrishnan SrikanthChief Science &Techn. OfficerMar 02 '26Sale1.4310,48314,991170,736Mar 04 07:07 PM
French Glendon E. IIIPresident and CEOMar 02 '26Sale1.4367,81396,9731,409,511Mar 04 07:06 PM
Rose Geoffrey BeranCHIEF COMMERCIAL OFFICERMar 02 '26Sale1.437,73211,057365,734Mar 04 07:04 PM
Lehman David AaronGENERAL COUNSELMar 02 '26Sale1.4312,23717,499240,755Mar 04 07:01 PM
STEVEN WILLIAMSONOfficerJan 22 '26Proposed Sale1.9548,89295,339Jan 22 04:02 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
DFMCU.S. Micro Cap Portfolio ETF Class SharesAUM: 212.10M
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B

News

latest 14 of 200
  • Pulmonx to Participate in Upcoming Investor Conferences (GlobeNewswire) +27.27% +25.60%
  • Pulmonx Returns To Revenue Growth And Beats On Cost Discipline, But The Revenue Guide Stays Unchanged (Earnings Whispers)
  • Pulmonx Reports Third Quarter 2026 Financial Results (GlobeNewswire)
  • Pulmonx to Report Third Quarter 2026 Financial Results on October 27, 2026 (GlobeNewswire)
  • Pulmonx Shares Fall Following Recent Gains (InvestorsHub)
  • Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.88%
  • Pulmonx to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Pulmonx Reports Second Quarter 2026 Financial Results (GlobeNewswire) +28.80%
  • Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference (GlobeNewswire)
  • Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026 (GlobeNewswire)
  • Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Pulmonx Corp (LUNG) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic ... (GuruFocus.com) +6.67%
  • Pulmonx Reports First Quarter 2026 Financial Results (GlobeNewswire)
  • Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-27-0.190-0.257-0.19022.8421.935
2026Q22026-07-29-0.240-0.280-0.23722.7622.395
2026Q12026-04-29-0.330-0.327-0.32620.5920.436
2025Q42026-03-04-0.250-0.385-0.25222.6021.736
2025Q32025-11-12-0.340-0.422-0.34121.5020.985
2025Q22025-07-30-0.380-0.394-0.37523.8623.656
2025Q12025-04-30-0.360-0.400-0.36222.5422.037
2024Q42025-02-19-0.330-0.448-0.33323.7722.296
2024Q32024-10-30-0.360-0.449-0.36020.3920.296
2024Q22024-07-31-0.390-0.424-0.39420.7820.156
2024Q12024-05-01-0.360-0.470-0.35618.8518.036
2023Q42024-02-21-0.360-0.409-0.36219.2818.246
2023Q32023-10-30-0.390-0.428-0.39117.6716.676
2023Q22023-08-02-0.430-0.436-0.42817.1915.866
2023Q12023-05-02-0.420-0.440-0.42214.5413.497
2022Q42023-02-22-0.380-0.416-0.38215.4313.987

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-3.160-2.218-0.90332.7331.74
2021FY-1.350-1.349-1.34748.4249.00
2022FY-1.590-1.620-1.58853.6652.16
2023FY-1.600-1.652-1.60268.6867.64
2024FY-1.440-1.558-1.44283.7982.32
2025FY-1.330-1.463-1.33090.5089.63
2026FY--0.968--91.03
2027FY--0.918--98.59
2028FY--0.733--109.39
2029FY--0.555--122.31
2030FY--0.387--136.13

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-10-2850424.8424.3025.30
2026Q4S2026-10-2750025.2824.6825.70
2026Q4S2026-10-1350025.2824.6825.70
2026Q4S2026-08-1052125.2824.6825.70
2026Q4S2026-07-3052125.2824.7025.70
2026Q4S2026-07-1450025.1424.7025.50
2026Q4S2026-05-2650225.1424.7025.50
2026Q4S2026-05-1961225.0024.3025.50
2026Q4S2026-04-3063225.0024.3025.50
2026Q4S2026-03-0554124.9423.7025.49
2026Q4S2026-01-2750024.5423.1026.11
2026Q4S2026-01-1050324.5423.1026.11
2026Q4S2025-11-1350424.5423.1026.11
2026Q4S2025-11-1130126.6426.1127.61

Estimate history

EPS, annual-0.522-0.584-0.903-1.347-1.588-1.602-1.442-1.327-1.0094
Period20182019202020212022202320242025TTM
EPS, quarterly-0.36-0.333-0.362-0.375-0.341-0.252-0.326-0.237-0.194
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual20.00432.59532.73348.41653.66268.67583.78990.49788.78
Period20182019202020212022202320242025TTM
Sales, quarterly20.38723.76522.53823.85921.50222.59820.58622.75622.835
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual35.42535.42535.69436.93237.55638.51639.78641.67443.551
Period20182019202020212022202320242025MRQ
Shares, quarterly39.48839.78640.24740.74441.24741.67442.23742.94843.551
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue88.7890.5083.7968.6753.6648.4232.7332.5920.00
Cost of Goods Sold Incl. D&A20.3523.4621.8918.3213.8012.7911.5310.187.72
Gross Profit68.4367.0461.9050.3539.8735.6321.2022.4112.29
Selling, General and Administrative Excl. Other107.83120.70117.89112.2998.5082.9353.5340.2527.34
Research and Development19.3819.4915.8518.0815.4013.067.466.056.99
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-39.41-53.66-55.99-61.94-58.64-47.30-32.33-17.84-15.05
Interest Expense4.203.153.513.231.070.833.182.322.52
Unusual Expense0.000.001.720.000.000.00-3.19--
Net Income Before Taxes-41.93-53.38-55.89-60.27-58.57-48.32-32.02-20.34-18.47
Income Taxes0.620.630.500.570.350.340.210.360.01
Consolidated Net Income-42.55-54.00-56.39-60.84-58.92-48.66-32.23-20.70-18.48
Net Income From Continuing Operations-42.55-54.00-56.39-60.84-58.92-48.66-32.23-20.70-18.48
Net Income-42.55-54.00-56.39-60.84-58.92-48.66-32.23-20.70-18.48
EPS (Recurring)-0.99-1.33-1.41-1.60-1.59-1.35-0.97-0.58-0.52
EPS (Basic, Before Extraordinaries)-1.01-1.33-1.44-1.60-1.59-1.35-0.90-0.58-0.52
EPS (Diluted)-1.01-1.33-1.44-1.60-1.59-1.35-0.90-0.58-0.52
EBITDA-38.22-52.51-54.39-59.99-54.64-44.14-31.93-16.64-14.78
Non-Operating Income (Expense)1.673.445.324.891.13-0.180.30-0.18-0.90
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense12.3916.7718.1317.4612.997.692.330.270.29
Price To Sales Ratio0.930.993.177.055.8323.9375.26--
Gross Margin77.0874.0873.8873.3274.2973.5964.7768.7761.42
Operating Margin-44.39-59.30-66.82-90.19-109.27-97.70-98.77-54.73-75.24
Net Margin-47.93-59.67-67.30-88.60-109.80-100.51-98.47-63.52-92.38
Shares Outstanding43.5541.6739.7938.5237.5636.9335.6935.4335.43
Market Capitalization129.78129.78268.12488.43315.361,181.422,461.872,378.05-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue22.8422.7620.5922.6021.5023.8622.5423.77
Cost of Goods Sold Incl. D&A5.545.114.645.065.556.756.206.17
Gross Profit17.3017.6415.9417.5415.9517.1016.3417.59
Selling, General and Administrative Excl. Other24.7926.7028.9027.4430.3431.9130.9131.01
Research and Development4.865.034.904.584.855.314.764.00
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-7.49-9.06-12.96-9.90-14.39-14.80-14.56-13.42
Interest Expense1.231.220.980.770.810.800.780.84
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-8.24-9.95-13.51-10.24-13.83-15.00-14.31-13.14
Income Taxes0.150.130.150.190.130.180.140.04
Consolidated Net Income-8.39-10.08-13.65-10.43-13.96-15.17-14.45-13.18
Net Income From Continuing Operations-8.39-10.08-13.65-10.43-13.96-15.17-14.45-13.18
Net Income-8.39-10.08-13.65-10.43-13.96-15.17-14.45-13.18
EPS (Recurring)-0.19-0.24-0.33-0.25-0.34-0.38-0.36-0.33
EPS (Basic, Before Extraordinaries)-0.19-0.24-0.33-0.25-0.34-0.38-0.36-0.33
EPS (Diluted)-0.19-0.24-0.33-0.25-0.34-0.38-0.36-0.33
EBITDA-7.17-8.73-12.64-9.67-14.05-14.40-14.29-13.12
Non-Operating Income (Expense)0.480.330.430.431.370.611.031.12
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.852.923.273.354.084.914.434.36
Price To Sales Ratio0.930.630.611.010.721.163.073.21
Gross Margin75.7677.5377.4577.6274.1971.6972.5174.02
Operating Margin-32.80-39.80-62.94-43.82-66.94-62.05-64.62-56.46
Net Margin-36.76-44.30-66.33-46.13-64.91-63.59-64.11-55.44
Shares Outstanding43.5542.9542.2441.6741.2540.7440.2539.79
Market Capitalization129.7854.9154.4991.1666.01104.27267.83268.12

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments70.01101.74117.34141.37180.27231.7928.354.12
Short Term Receivables12.6614.9213.429.387.024.576.003.42
Inventories15.8516.9116.7414.5616.2910.745.613.32
Other Current Assets2.972.672.823.644.422.891.110.44
Total Current Assets101.48136.25150.32168.95208.00249.9941.0711.31
Net Property, Plant & Equipment20.2521.457.4310.5012.8910.457.460.38
Total Investments and Advances0.000.0014.395.9210.940.000.000.00
Intangible Assets2.332.332.362.492.612.732.862.98
Deferred Tax Assets4.664.861.170.410.48---
Other Assets5.232.823.275.810.730.542.140.35
Total Assets133.95167.71178.95194.08235.65263.7153.5315.01
Short Term Debt Incl. Current Port. of LT Debt1.323.955.233.322.292.240.450.00
Accounts Payable3.903.831.501.761.581.472.681.29
Income Tax Payable0.260.050.090.020.150.090.230.05
Other Current Liabilities14.5716.6116.3413.4013.538.7210.806.74
Total Current Liabilities20.0624.4423.1618.4917.5512.5314.168.07
Long Term Debt55.0552.5236.2021.0824.1724.99226.71174.15
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Deferred Tax Liabilities4.734.951.280.500.520.060.040.05
Other Liabilities0.000.000.000.000.180.000.000.07
Total Liabilities79.8481.9060.6440.0842.4137.57240.91182.34
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity54.1285.81118.31154.01193.24226.13-187.38-167.33
Total Shareholders Equity54.1285.81118.31154.01193.24226.13-187.38-167.33
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity54.1285.81118.31154.01193.24226.13-187.38-167.33
Total Liabilities & Stockholders Equity133.95167.71178.95194.08235.65263.7153.5315.01
Book Value Per Share1.302.163.074.105.236.34-5.29-4.72
Tangible Book Value Per Share1.242.103.014.035.166.26-5.37-4.81
Full-Time Employees296291279269253220180-
Price to Book Ratio3.792.853.881.936.1310.89-11.49-
Return on Assets-35.80-32.54-32.62-27.42-19.49-20.32-60.41-
Return on Equity-77.19-55.25-44.68-33.94-23.21-166.33--
Return on Invested Capital-49.47-40.77-39.38-33.65-22.38-12.83-52.64-270.71
Quick Ratio4.274.885.778.3510.9219.102.500.99
Current Ratio5.065.586.499.1411.8519.962.901.40

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-42.55-54.00-56.39-60.84-58.92-48.66-32.23-20.70-18.48
Depreciation0.891.051.491.554.010.870.481.200.27
Other Funds (Non Cash)18.1222.4325.0724.2416.7914.215.901.141.34
Funds from Operations-23.55-30.52-29.83-35.05-38.07-33.59-25.82-18.37-17.07
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-2.54-1.93-1.70-2.56-7.06-7.84-4.81-2.40-1.32
Income Taxes Payable-0.010.18-0.090.09-0.120.02-0.150.18-0.03
Cash from Operating Activities-26.09-32.45-31.54-37.61-45.14-41.43-30.63-20.77-18.39
Capital Expenditures-0.03-0.45-1.45-0.81-1.32-3.67-0.91-0.72-0.32
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.02
Purchase or Sale of Investments0.0030.9318.92-1.20-2.91-42.5813.61-13.510.50
Purchase of Investments0.00-5.65-27.91-46.20-47.19-52.580.00-21.450.00
Sale Or Maturity of Investments0.0036.5946.8445.0044.2810.0013.617.940.50
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.0330.4817.48-2.01-4.22-46.2612.69-14.230.20
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.551.001.461.492.564.50203.8840.190.11
Repurchase of Common Pref Stock0.000.000.000.00-0.03-0.03-0.02-0.010.00
Sale of Common Pref Stock0.551.001.461.492.594.52203.9040.200.11
Proceedsfrom Stock Options0.400.751.241.181.942.65201.1939.670.08
Issuance or Reduction of Debt, Net1.68-0.10-0.1019.91-0.090.0030.966.0012.00
Change in Long Term Debt1.68-0.10-0.1019.91-0.090.0030.966.0012.00
Issuance of Long Term Debt38.780.000.0020.000.000.0052.746.0012.00
Reduction of Long Term Debt-37.10-0.10-0.10-0.09-0.090.00-21.790.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.00-0.570.00
Other Financing Activities Uses0.000.000.000.000.000.000.00-0.570.00
Cash from Financing Activities2.240.901.3621.402.474.50234.8345.6212.11
Exchange Rate Effect0.02-0.090.080.030.140.110.130.020.15
Net Change in Cash-23.86-1.15-12.62-18.18-46.74-83.08217.0310.64-5.93
Free Cash Flow-26.12-32.90-32.98-38.42-46.45-45.10-31.54-21.48-18.71
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.05-0.010.02-0.01-0.20

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments52.9556.1061.8370.0176.8184.48
Short Term Receivables12.5312.7311.2712.6614.3016.40
Inventories15.4416.3916.3115.8516.2516.18
Other Current Assets2.952.913.142.973.882.76
Total Current Assets83.8688.1392.55101.48111.23119.82
Net Property, Plant & Equipment18.8019.1519.7120.2520.7221.30
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets2.332.332.332.332.332.33
Deferred Tax Assets---4.66--
Other Assets5.225.115.375.233.993.73
Total Assets110.21114.73119.97133.95138.28147.19
Short Term Debt Incl. Current Port. of LT Debt1.491.381.341.321.241.22
Accounts Payable4.514.673.473.906.426.56
Income Tax Payable0.170.260.330.260.190.20
Other Current Liabilities14.5714.0913.7614.5715.0314.47
Total Current Liabilities20.7420.4118.9120.0622.8822.45
Long Term Debt54.8654.8354.9555.0555.3255.61
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.070.060.074.730.050.04
Other Liabilities0.340.240.280.000.000.00
Total Liabilities76.0175.5474.2079.8478.2578.10
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity34.2039.2045.7654.1260.0369.09
Total Shareholders Equity34.2039.2045.7654.1260.0369.09
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity34.2039.2045.7654.1260.0369.09
Total Liabilities & Stockholders Equity110.21114.73119.97133.95138.28147.19
Book Value Per Share0.790.911.081.301.461.70
Tangible Book Value Per Share0.730.861.031.241.401.64
Full-Time Employees---296--
Price to Book Ratio3.791.200.991.520.961.34
Return on Assets-34.25-36.74-39.31-35.80-37.13-35.61
Return on Equity-90.31-88.87-86.22-77.19-73.73-66.88
Return on Invested Capital-9.43-10.72-13.56-9.55-12.10-12.17
Quick Ratio3.303.524.034.274.154.62
Current Ratio4.044.324.905.064.865.34

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-8.39-10.08-13.65-10.43-13.96-15.17
Depreciation0.210.220.220.230.250.30
Other Funds (Non Cash)4.483.934.924.795.656.25
Funds from Operations-3.69-5.93-8.52-5.40-8.06-8.62
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.470.26-1.58-1.68-0.134.67
Income Taxes Payable-0.08-0.070.060.09-0.010.07
Cash from Operating Activities-3.23-5.67-10.10-7.08-8.19-3.96
Capital Expenditures-0.01-0.00-0.01-0.01-0.09-0.05
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.008.805.52
Purchase of Investments0.000.000.000.000.00-1.73
Sale Or Maturity of Investments0.000.000.000.008.807.25
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.01-0.00-0.01-0.018.715.47
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.210.000.240.110.200.03
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.210.000.240.110.200.03
Proceedsfrom Stock Options0.200.000.200.000.200.00
Issuance or Reduction of Debt, Net0.00-0.051.78-0.05-0.00-0.05
Change in Long Term Debt0.00-0.051.78-0.05-0.00-0.05
Issuance of Long Term Debt0.000.0038.780.000.000.00
Reduction of Long Term Debt0.00-0.05-37.00-0.05-0.00-0.05
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.21-0.052.030.060.20-0.02
Exchange Rate Effect-0.120.00-0.100.240.35-0.58
Net Change in Cash-3.15-5.73-8.18-6.801.080.91
Free Cash Flow-3.24-5.67-10.11-7.10-8.27-4.00

Revenue breakdown

Surgical & Medical Instruments & Apparatus2024: 83.79M 2025: 90.50M
Asia Pacific2024: 4.44M 2025: 6.23M
EMEA2024: 22.33M 2025: 26.99M
Other International Geographical Areas2024: 556.00K 2025: 260.00K
United States2024: 56.47M 2025: 57.02M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.02%0.8M39.0M646.54K
2026-10-151.82%0.7M38.5M484.09K
2026-09-302.09%0.8M38.5M478.72K
2026-09-152.21%0.8M38.5M580.16K
2026-08-312.54%1.0M38.4M572.39K
2026-08-142.79%1.1M38.3M579.36K
2026-07-312.77%1.1M38.3M530.18K
2026-07-152.80%1.1M37.7M484.32K
2026-06-303.05%1.1M37.7M479.85K
2026-06-156.01%2.3M37.7M434.32K
2026-05-297.39%2.8M38.1M556.09K
2026-05-156.84%2.7M39.5M548.71K
2026-04-309.75%3.6M36.5M518.96K
2026-04-157.67%2.8M36.7M483.33K
2026-03-317.79%2.9M36.7M510.99K
2026-03-138.99%3.3M36.7M538.18K
2026-02-279.26%3.3M35.8M560.38K
2026-02-139.15%3.3M35.8M655.55K
2026-01-307.86%2.8M35.8M826.17K
2026-01-157.35%2.6M35.8M2.70M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.100.750.222.7931,1510.000.765-0.0160.001
call5.000.000.050.052.3902150.000.109-0.0120.001
call7.500.000.750.003.5500.000.000.082-0.0140.001
put2.500.000.150.231.63779.000.00-0.206-0.0120.001
put5.001.802.450.004.9890.000.00-0.890-0.0110.001
put7.504.105.100.007.3710.000.00-0.918-0.0130.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-05SCHEDULE 13G/ASEC
2026-11-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-278-KCurrent report2026-10-27SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-29SCHEDULE 13G/ASEC
2026-07-298-KCurrent report2026-07-29SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-048-KCurrent report2026-06-04SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-05-19SDSpecialized Disclosure ReportSEC
2026-05-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-298-KCurrent report2026-04-29SEC
2026-04-22ARSAnnual report to security holders. 2025-12-31SEC
2026-04-22DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-22DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-04SEC
2026-03-27SCHEDULE 13G/ASEC
2026-03-10S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0900177.05K4
2026-080000
2026-070000
2026-0600144.03K5
2026-050000
2026-040000
2026-0300140.52K4
2026-020000
2026-010000
2025-120086.29K4
2025-110000

Institutional holders

Manager% owned
PRIMECAP MANAGEMENT CO/CA/10.92%
MORGAN STANLEY6.92%
Soleus Capital Management, L.P.6.60%
VANGUARD CAPITAL MANAGEMENT LLC3.86%
ExodusPoint Capital Management, LP2.90%
Almitas Capital LLC2.52%
BlackRock, Inc.2.09%
Stonepine Capital Management, LLC1.93%
JANE STREET GROUP, LLC1.80%
BRAIDWELL LP1.78%

Funds

Fund% owned
PRIMECAP Odyssey Aggressive Growth Fund8.29%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.73%
VANGUARD EXTENDED MARKET INDEX FUND1.03%
VANGUARD EXPLORER FUND0.91%
Fidelity Small Cap Index Fund0.87%
VANGUARD RUSSELL 2000 INDEX FUND0.45%
Fidelity Extended Market Index Fund0.36%
iShares Micro-Cap ETF0.32%
Fidelity Nasdaq Composite Index Fund0.26%
Fidelity Total Market Index Fund0.17%

OakChart. LUNG. Cached 15 minutes.